Tagged with MS

Pharma The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare system for Italy, and the vision she has for her company. At the beginning of the New Year, how is…

Pharma Automation and consolidation have affected pharmaceutical companies worldwide, and Puerto Rico is no exception. The island has benefited from the trend towards lower volume, higher value products which often use the smaller plants Puerto Rico offers. Some companies, like Merck, are transforming their sites from pure manufacturing to commercialization. These trends point to…

Pharma A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through complementary health insurance, and breaking with the egalitarian principle that everybody should be reimbursed to the same extent irrespective of…

Pharma Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system does not capture the benefits that the next generation of gene therapy products deliver over time, transforming chronic diseases into…

Pharma Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall to society, as well as the company’s changing role in the Sanofi organization with the addition of the oncology and…

pharma   The Thai pharmaceutical market is growing due to an aging, wealthier local population and a large medical tourism sector. International companies must however adapt their strategies to suit the Thai market; as must domestic concerns. With an estimated value of USD 4.5 billion, Thailand is Southeast Asia’s second largest…

Pharma The Managing Director of MSD Egypt highlights MSD’s unique incentives to further collaborate with the Egyptian medical community and explains how market peculiarities shape product launches in developing countries like Egypt. As newly appointed Managing Director for MSD Egypt, could you please outline your objectives and ambitions in the Egyptian…

pharma Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic player across the whole of Europe and why 2015 was a significant year for the group, receiving European marketing approval…

pharma Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed by the increasingly high cost of innovative drugs on the healthcare budget. Prof. Smits highlights the benefits that could be…

Pharma Leo Le Duc, Director of Amsterdam Science Park, explains the potential of Amsterdam Science Park as a world-class eco-system for start-ups, mature companies, research centers and students, as well as how the largest beta-science cluster in Northern Europe will help to globally establish Amsterdam as a “City of Knowledge.”  You…

Pharma Abbvie GM for South Africa Christo Kruger highlights the various types of projects that the Public Health Enhancement Fund (PHEF) is pursuing to help alleviate the country’s currently overburdened healthcare system. He also describes AbbVie’s role in this industry collective, and also depicts the company’s developing foothold within the South…

France The Director of the Social Security talks about the need to strengthen the sustainability of the French social security system, how France is attached to its unique system combining a high level of public coverage, with the strong involvement of the private sector, helping to provide access to innovation for…